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Background: Data and statistics on cancer mortality over the last decades are available for most
developed countries, while they are more difficult to obtain, in a standardized and comparable
format, for countries of Latin America.
Patients and methods: Age standardized (world population) mortality rates around the year 2000,
derived from the WHO database, are presented for 14 selected cancers and total cancer in
10 countries of Latin America, plus, for comparative purposes, Canada and the USA. Trends in
mortality are also given over the period 1970–2000.
Results: In 2000, the highest total cancer mortality for males was observed in Argentina and Chile,
with rates comparable to those of Canada and the USA, i.e. about 155/100 000. For women, Chile
and Cuba had the highest rates in Latin America (114 and 103/100 000, respectively), again compar-
able to those of North America (around 105/100 000). These reflect the comparatively high mortality
from cancer of the stomach (for Chile), lung and intestines (for Argentina) in men, and of stomach
and uterus (for Chile), intestines and lung (for Cuba) in women. Colombia, Ecuador and Mexico had
the lowest total cancer mortality for men, due to low mortality from stomach, colorectal and lung
cancer. For women, the lowest rates were in Brazil and Puerto Rico, reflecting their low stomach
and cervical cancer rates. In Argentina, Chile, Colombia, Costa Rica and Venezuela cancer mortality
rates tended to decline, particularly in men. Rates were stable in Ecuador and Puerto Rico, and were
increasing in Mexico and Cuba.
Conclusions: Mortality from some common cancers (including colorectal and lung) is still low in
Latin America compared with Canada and the USA, and decreasing trends have been observed in
the last decades for some cancer sites (including stomach, uterus, lung and other tobacco-related
cancers) in several countries. However, mortality from female lung and breast cancers has been
increasing in most countries of Latin America, and several countries still show an extremely elev-
ated mortality from cancer of the cervix. Selected neoplasms amenable to treatment, including testis
and leukemias, also show unsatisfactory trends in Latin America.
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Introduction
Data and statistics on cancer mortality over the last few dec-
ades are easily available for most developed countries, includ-
ing Europe [1], North America and Japan [2–5], while they
are more difficult to obtain, in a standardized and comparable
format, for countries of Latin America [3, 6].
In the early 1990s, a summary overview was published of
cancer mortality in the Americas between 1955 and 1989 [6].
In the present report, trends in cancer mortality in selected
countries of the Americas (including, mainly for comparative
purposes, the USA and Canada) have been updated to the year
2000. Since long-term trends provide useful information to
understand recent patterns and to project most likely future
trends [7], this paper also gives a summary overview of trends
since 1970. The major aim of the present work is to provide a
comprehensive documentation of the patterns of cancer mor-
tality trends in the Americas, and has therefore relevant impli-
cations for further investigation and public health intervention.
Patients and methods
Certified deaths from 14 selected cancer sites and for total cancer mortality
for the calendar period considered (1970–2000), stratified for sex and
5-year age groups, were derived from the WHO database [8] for
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Table 1. Calendar years and countries for which data were missing
Country Cancer sites (ICD IX)
Mouth and pharynx (140–149) Esophagus (150) Stomach (151) Intestines (152–154, 159.0) Larynx (161)
Argentina 1971–1976, 1998, 1999 1971–1976, 1998, 1999 1971–1976, 1998, 1999 1971–1976, 1998, 1999 1971–1976, 1998, 1999
Brazila 1970–1985, 1996–1999 1970–1985, 1996–1999 1970–1985, 1996–1999 1970–1985, 1996–1999 1970–1985, 1996–1999
Chile – – – – –
Colombia 1970, 1971, 1973, 1978–1983,
1987–1990, 1999
1970, 1971, 1973, 1978–1983,
1987–1990, 1999
1970, 1971, 1973, 1978–1983,
1987–1990, 1999
1970, 1971, 1973, 1978–1983,
1987–1990, 1999
1970, 1971, 1973, 1978–1983,
1987–1990, 1999
Costa Rica – – – – –
Cuba – – – – –
Ecuador 1976, 1981, 1983, 1989 1976, 1981, 1983, 1989 1976, 1981, 1983, 1989 1976, 1981, 1983, 1989 1976, 1981, 1983, 1989
Mexico 1977, 1984 1977, 1984 1977, 1984 1977, 1984 1977, 1984
Puerto Rico 1978 1978 1978 1978 1978
Venezuela 1984, 1991, 1995 1984, 1991, 1995 1984, 1991, 1995 1984, 1991, 1995 1984, 1991, 1995
Canada 1999 1999 1999 1999 1999
USA – – – – –
Lung (162) Bone (170) Breast (174) Uterus (179–182) Ovary (183)
Argentina 1971–1976, 1998, 1999 1971–1976, 1998, 1999 1971–1976, 1998, 1999 1971–1976, 1998, 1999 1970–1979, 1982–1996, 1998, 1999
Brazila 1970–1985, 1996–1999 1970–1985, 1996–1999 1970–1985, 1996–1999 1970–1985, 1996–1999 1970–1999
Chile – – – – 1970–1982, 1984–1996
Colombia 1970, 1971, 1973, 1978–1983,
1987–1990, 1999
1970, 1971, 1973, 1978–1983,
1987–1990, 1999
1970, 1971, 1973, 1978–1983,
1987–1990, 1999
1970, 1971, 1973, 1978–1983,
1987–1990, 1999
1970–1996, 1999
Costa Rica – – – – 1970–1996
Cuba – – – – 1970–1999
Ecuador 1976, 1981, 1983, 1989 1976, 1981, 1983, 1989 1976, 1981, 1983, 1989 1976, 1981, 1983, 1989 1970–1996
Mexico 1977, 1984 1977, 1984 1977, 1984 1977, 1984 1970, 1975–1997
Puerto Rico 1978 1978 1978 1978 1970–1998
Venezuela 1984, 1991, 1995 1984, 1991, 1995 1984, 1991, 1995 1984, 1991, 1995 1975, 1979, 1981–1995
Canada 1999 1999 1999 1999 1999
USA – – – – 1978
Prostate (185) Testis (186) Bladder (188) Leukemias (204–208) All neoplasms (140–239)
Argentina 1971–1976, 1998, 1999 1970–1979, 1982–1996, 1998, 1999 1970–1978, 1998, 1999 1971–1976, 1998, 1999 1971–1976, 1998, 1999
Brazila 1970–1985, 1996–1999 1970–1999 1970–1985, 1996–1999 1970–1985, 1996–1999 1970–1985, 1996–1999
Chile – 1970–1982, 1984–1996 1970–1979 – –
Colombia 1970, 1971, 1973, 1978–1983,
1987–1990, 1999
1970–1996, 1999 1970–1983, 1987–1990, 1999 1970, 1971, 1973, 1978–1983,
1987–1990, 1999
1970, 1971, 1973, 1978–1983,
1987–1990, 1999
Costa Rica – 1970–1996 1970–1979 – –
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10 countries of Latin America with available and updated mortality and
population data, i.e. Argentina, Brazil, Chile, Colombia, Costa Rica,
Cuba, Ecuador, Mexico, Puerto Rico and Venezuela, plus Canada and the
USA. For Brazil, data from only the south, south-east and central-west
regions were available (about 100 million inhabitants).
During the calendar periods considered, three different Revisions of the
International Classification of Diseases (ICD) were used [9–11]. Classifi-
cation of cancer deaths was thus recoded for all calendar periods accord-
ing to the IX Revision of the ICD [10]. To improve data comparability
between different countries and calendar periods, we pooled together all
intestinal cancers (chiefly colon and rectum), all uterine cancers (cervix
and corpus) and all leukemias. We did not consider some rare cancers (i.e.
gallbladder, sarcomas, lymphomas and thyroid), and a few other sites (i.e.
liver, pancreas, skin, kidney and brain) which involve major difficulties or
inconsistencies in diagnosis and certification.
Estimates of the resident populations, based on official censuses, were
obtained from the same WHO database [8] whenever available, and from
the Pan American Health Organization (PAHO) [12], when the WHO data
were unavailable. Since the PAHO database provided only data for broad
age groups, subsequent quinquennia of age were estimated by interpolat-
ing from the WHO distribution of the last year available for each country.
From the matrices of certified deaths and resident population, age-
specific rates for each 5-year age group and calendar period were com-
puted, for men and women. Age-standardized rates per 100 000 popu-
lation, at all ages and truncated at age 35–64 years, were computed by
the direct method, on the basis of the world standard population [13].
In a few countries, data were missing for one or more calendar years
(Table 1). No extrapolation was made for missing data.
Results and discussion
This is essentially a descriptive report, and no inference is
made on the statistical significance of rates and trends. A few
general comments are, however, included to assist in critical
reading and interpretation of results. First, it is important to
consider problems related to random variation, which are
greater in smaller populations and for rarer cancers. Secondly,
and more complex, there are problems of death certification
reliability and validity, which may differ in various countries
[14–16]. In general, for several common cancer sites, includ-
ing lung, stomach, colorectum and breast, death certification is
sufficiently reliable to permit meaningful inference on trends
in most American countries, particularly within countries and
under age 65 years. Greater caution is required for a few
countries and cancer sites, whose diagnosis and certification
can be appreciably influenced by the availability and utilization
of diagnostic techniques and the accuracy of death certifica-
tion, including, among others, bone, prostate and leukemias.
Table 2 includes, for the 14 selected cancers and for each
country and sex, the observed number of deaths and the age-
standardized (world standard) overall and truncated (35–64
years) mortality rates per 100 000 over the most recent year
(2000, whenever available). Figure 1 gives the histograms of
the overall age-standardized death rates for total cancer mor-
tality for each cancer site (by country and sex) for the year
2000 (or the most recent calendar year available). Figure 2
shows the trends in the world standardized rates (at all ages
and truncated at 35–64 years) for each cancer site in the 12T
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Table 2. Certified number of deaths and age-standardized (world
standard) overall and truncated 35–64 years mortality rates per 100 000
for 14 cancer sites plus all cancers, in selected countries of the Americas
in 2000 (unless mentioned in parentheses)
Country Men Women
Deaths
no.
World
standard
Truncated
35–64
Deaths
no.
World
standard
Truncated
35–64
Mouth and pharynx
Argentina 617 3.34 6.66 200 0.74 1.02
Brazil (1995) 2576 6.64 13.15 536 1.15 1.77
Chile (1999) 125 2.16 3.30 47 0.55 0.57
Colombia
(1999)
250 2.00 2.41 181 1.22 1.41
Costa Rica 37 2.66 3.51 17 1.13 1.25
Cuba 377 5.74 9.87 115 1.48 1.94
Ecuador 54 1.35 1.57 22 0.48 0.48
Mexico 498 1.70 2.19 275 0.77 0.86
Puerto Rico 111 5.22 9.98 25 0.86 1.09
Venezuela 173 2.47 3.78 86 1.07 1.19
Canada 594 2.77 4.46 307 1.04 1.36
USA 4952 2.73 4.81 2540 0.98 1.36
Esophagus
Argentina 1398 7.16 9.50 582 2.05 2.14
Brazil (1995) 3024 7.99 14.23 966 2.09 3.10
Chile (1999) 446 7.54 5.30 305 3.53 2.75
Colombia
(1999)
411 3.40 3.19 228 1.50 1.41
Costa Rica 29 2.27 2.63 17 1.04 0.23
Cuba 293 4.52 7.31 100 1.40 2.10
Ecuador 74 2.00 1.39 25 0.57 0.74
Mexico 551 1.89 2.23 219 0.61 0.59
Puerto Rico 117 5.09 7.26 38 1.24 0.97
Venezuela 165 2.44 3.13 54 0.67 0.45
Canada 1052 4.79 6.55 340 1.11 1.02
USA 9279 4.98 7.60 2953 1.09 1.32
Stomach
Argentina 1965 9.93 12.31 1004 3.75 5.00
Brazil (1995) 5710 15.17 20.65 2805 5.90 7.32
Chile (1999) 2014 33.75 35.31 1024 12.11 11.86
Colombia
(1999)
2469 19.93 24.76 1643 10.97 12.02
Costa Rica 356 27.20 28.55 212 13.68 12.32
Cuba 463 6.86 9.62 261 3.52 4.68
Ecuador 781 20.66 21.67 586 13.58 15.02
Mexico 2760 9.32 11.06 2249 6.36 7.89
Puerto Rico 167 6.97 9.07 110 3.42 3.01
Venezuela 1013 14.89 15.47 676 8.46 8.88
Canada 1195 5.16 5.75 793 2.55 3.01
USA 7328 3.65 4.65 5317 1.84 2.27
Table 2. (Continued)
Country Men Women
Deaths
no.
World
standard
Truncated
35–64
Deaths
no.
World
standard
Truncated
35–64
Intestine
Argentina 2986 14.89 16.20 2609 9.31 10.97
Brazil (1995) 2341 6.11 7.78 2718 5.67 6.86
Chile (1999) 482 7.96 7.87 632 7.36 6.87
Colombia
(1999)
700 5.47 7.12 887 5.84 6.86
Costa Rica 90 6.96 6.83 129 8.53 8.66
Cuba 736 10.46 11.87 999 12.84 15.06
Ecuador 131 3.42 4.08 191 4.48 4.95
Mexico 1316 4.38 5.58 1306 3.65 4.96
Puerto Rico 275 11.91 15.89 243 8.05 10.30
Venezuela 520 7.49 8.73 543 6.78 8.62
Canada 3549 15.43 17.82 3094 9.75 11.39
USA 28 462 13.96 16.33 29 015 9.82 11.48
Larynx
Argentina 849 4.50 7.67 93 0.37 0.65
Brazil (1995) 1819 4.81 9.06 254 0.56 0.98
Chile (1999) 101 1.73 1.80 24 0.29 0.28
Colombia
(1999)
330 2.72 3.10 101 0.70 0.77
Costa Rica 22 1.69 1.08 2 0.13 0.23
Cuba 472 7.26 11.69 89 1.23 1.79
Ecuador 36 0.90 0.88 12 0.27 0.13
Mexico 695 2.44 2.79 153 0.44 0.49
Puerto Rico 70 3.21 5.60 10 0.32 0.32
Venezuela 240 3.54 5.28 41 0.54 0.49
Canada 416 1.87 2.34 90 0.33 0.28
USA 3041 1.62 2.39 820 0.35 0.49
Lung
Argentina 6691 35.02 54.70 1718 6.88 11.41
Brazil (1995) 7689 20.73 28.67 2899 6.32 9.40
Chile (1999) 1243 21.28 27.15 600 7.52 8.45
Colombia
(1999)
1762 14.60 17.51 1115 7.76 10.15
Costa Rica 165 12.74 9.84 90 6.00 3.89
Cuba 2546 38.29 53.76 1153 16.72 27.10
Ecuador 289 7.71 8.18 161 3.80 4.92
Mexico 4259 14.90 15.21 2014 5.86 6.88
Puerto Rico 399 17.52 21.07 193 6.87 7.57
Venezuela 1310 18.95 25.90 796 10.11 15.80
Canada 9650 43.13 50.30 6484 24.65 36.98
USA 90 469 46.92 57.31 65 052 26.21 35.61
Bone
Argentina 235 1.23 1.76 175 0.69 0.81
Brazil (1995) 430 1.00 1.23 294 0.61 0.73
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Table 2. (Continued)
Country Men Women
Deaths
no.
World
standard
Truncated
35–64
Deaths
no.
World
standard
Truncated
35–64
Chile (1999) 64 0.96 0.89 57 0.69 0.32
Colombia
(1999)
142 0.91 1.18 88 0.50 0.45
Costa Rica 15 0.96 1.03 13 0.74 0.57
Cuba 82 1.27 1.97 71 1.14 1.40
Ecuador 51 1.21 1.50 56 1.22 1.22
Mexico 179 0.50 0.61 171 0.43 0.65
Puerto Rico 17 0.66 0.74 19 0.74 0.64
Venezuela 93 1.05 1.04 65 0.73 1.04
Canada 81 0.46 0.38 66 0.35 0.17
USA 682 0.41 0.41 530 0.26 0.22
Breast
Argentina 5015 20.65 37.14
Brazil (1995) 5831 12.45 25.04
Chile (1999) 973 12.55 22.32
Colombia
(1999)
1434 9.46 19.09
Costa Rica 182 11.85 24.28
Cuba 1012 14.82 28.22
Ecuador 287 6.97 14.10
Mexico 3468 9.90 21.27
Puerto Rico 338 13.75 27.96
Venezuela 1107 13.34 27.17
Canada 4857 18.24 32.60
USA 41 872 17.56 31.95
Uterus
Argentina 2422 10.68 21.49
Brazil (1995) 4379 9.27 17.88
Chile (1999) 908 11.58 19.43
Colombia
(1999)
2126 13.93 27.20
Costa Rica 174 11.60 18.04
Cuba 958 14.13 28.09
Ecuador 627 14.72 26.50
Mexico 5198 14.82 28.36
Puerto Rico 119 4.88 9.07
Venezuela 1437 16.92 30.77
Canada 1038 3.79 6.14
USA 10 786 4.59 7.92
Ovary
Argentina 1133 4.74 8.73
Brazil (1995) – – –
Chile (1999) 318 4.21 7.63
Colombia
(1999)
456 3.08 5.60
Costa Rica 50 3.50 6.15
Table 2. (Continued)
Country Men Women
Deaths
no.
World
standard
Truncated
35–64
Deaths
no.
World
standard
Truncated
35–64
Cuba 218 3.35 6.85
Ecuador 98 2.26 4.04
Mexico 1186 3.44 6.39
Puerto Rico 79 2.93 4.39
Venezuela 305 3.64 5.92
Canada 1429 5.34 8.41
USA 14 453 5.84 9.04
Prostate
Argentina 3510 16.28 6.48
Brazil (1995) 4380 11.95 6.11
Chile (1999) 1224 19.85 5.44
Colombia
(1999)
1828 14.54 6.64
Costa Rica 282 21.70 4.58
Cuba 1844 23.06 10.49
Ecuador 580 15.32 5.26
Mexico 3852 13.14 5.62
Puerto Rico 524 17.49 6.77
Venezuela 1408 22.26 8.60
Canada 3718 13.86 5.10
USA 31 078 12.73 5.27
Testis
Argentina 132 0.71 0.78
Brazil (1995) – – –
Chile (1999) 105 1.30 1.55
Colombia
(1999)
77 0.40 0.40
Costa Rica 12 0.68 0.70
Cuba 17 0.28 0.33
Ecuador 25 0.48 0.61
Mexico 311 0.66 0.60
Puerto Rico 6 0.28 0.16
Venezuela 37 0.36 0.47
Canada 37 0.20 0.26
USA 338 0.21 0.32
Bladder
Argentina 944 4.61 4.03 318 1.04 0.86
Brazil (1995) 979 2.64 2.11 431 0.90 0.92
Chile (1999) 152 2.51 1.84 94 1.09 0.75
Colombia
(1999)
204 1.61 1.34 113 0.77 0.71
Costa Rica 35 2.76 1.38 15 0.98 0.75
Cuba 306 4.00 3.05 96 1.15 0.93
Ecuador 36 0.98 0.44 29 0.63 0.28
Mexico 398 1.38 1.08 220 0.62 0.57
Puerto Rico 65 2.53 2.28 37 1.12 0.96
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countries of the Americas for 5-year calendar periods from
1970–1974 to 1995–99 and year 2000, for men and women.
Different scales were adopted for each neoplasm and country,
in order to provide more easily readable and interpretable
patterns.
Mouth and pharynx
In the year 2000, the highest rates for oral and pharyngeal
cancer mortality in men were observed in Brazil, Cuba and
Puerto Rico with values around 5–6/100 000, i.e. 1.5- to 2.0-
fold higher than values from Canada and the USA. Colombia,
Ecuador and Mexico showed the lowest rates, with values
around 1–2/100 000. As in Canada, the USA and several
countries of Europe [1], a leveling or even a fall in mortality
rates from oral and pharyngeal cancer was observed in various
Latin American countries, starting from the 1970s in Puerto
Rico and Venezuela, since the early 1980s in Argentina and
Chile, and since the late 1980s in Colombia. In Mexico, mor-
tality from cancers of the mouth and pharynx in men increased
between 1970 and 1989, and leveled off thereafter. In Cuba,
after a favorable trend between 1970 and 1985, rates have
started to increase again, notwithstanding a nationwide screen-
ing program implemented for a number of years [17]. No
clear trend was observed in Costa Rica and Ecuador. Mortality
rates for cancer of the mouth and pharynx in women were
very low (between 0.5 and 1.5/100 000) and showed no
appreciable trends in any country, except in Venezuela, where
rates continuously declined between the 1970s (characterized
by particularly high rates) and the 1980s, and tended to level
off thereafter.
Since alcohol drinking and tobacco smoking are the major
risk factors for cancer of the mouth and pharynx [18–21],
recent favorable trends in mortality in most American
countries would indicate favorable changes in the exposure to
these two risk factors over the last decades [22]. Additional
factors, mainly related to improvement in diet [23] and mate´
drinking—particularly in Argentina and Brazil [24]—may also
have had some role on recent trends.
Esophagus
In 2000, Argentina, Brazil, Chile and Puerto Rico had the
highest rates for male esophageal cancer mortality (values
about 7–8/100 000). The same countries were also character-
ized by high esophageal mortality in women (values between
2 and 3/100 000). Ecuador and Mexico showed very low mor-
tality rates from esophageal cancer in both sexes. In some of
the high risk countries, rates steadily declined in both sexes in
the last three decades. Similar decreasing trends were found in
most other Latin American countries, including Venezuela,
which started from high rates in the 1970s, Colombia, Costa
Rica and Ecuador, where the decline started since the late
1980s. In Cuba and Mexico, as well as in Canada and the
USA, upward trends in rates were observed in men, but not in
women.
In most countries, mortality patterns were similar for eso-
phageal and oral and pharyngeal cancers, underlining simi-
larities of risk factors for these two neoplasms, i.e. alcohol
drinking and tobacco smoking [18, 19, 21], plus mate´ drinking
[25] and other dietary items [23]. The rising trends observed
in the last decades in Canada and in the USA are probably
due to an increased incidence and mortality from adenocarci-
noma of the esophagus, associated with overweight, obesity
and gastro-esophageal reflux besides tobacco smoking, but not
to alcohol drinking [26–28].
Stomach
Over recent calendar periods, male stomach cancer mortality
was exceedingly high in some Latin American countries,
including Chile, Costa Rica and Ecuador (with rates higher
Table 2. (Continued)
Country Men Women
Deaths
no.
World
standard
Truncated
35–64
Deaths
no.
World
standard
Truncated
35–64
Venezuela 125 1.89 1.62 61 0.75 0.50
Canada 1082 4.34 3.17 437 1.20 0.92
USA 8163 3.65 2.83 3839 1.15 0.95
Leukemia
Argentina 969 4.96 4.95 764 3.20 3.32
Brazil (1995) 1554 3.61 4.23 1340 2.76 3.43
Chile (1999) 282 4.29 4.72 252 3.22 3.38
Colombia
(1999)
766 4.52 4.39 656 3.58 4.10
Costa Rica 82 5.20 4.82 55 3.29 3.77
Cuba 268 4.36 4.95 223 3.35 4.69
Ecuador 225 4.23 4.66 150 2.73 3.62
Mexico 1739 4.20 4.18 1562 3.54 4.20
Puerto Rico 95 4.02 4.59 85 3.15 4.62
Venezuela 410 4.31 4.02 335 3.31 3.97
Canada 1190 5.40 5.12 858 2.92 2.90
USA 11 777 5.94 5.56 9562 3.58 3.80
All neoplasms
Argentina 30 253 153.52 191.32 25 237 98.65 147.22
Brazil (1995) 44 774 116.97 158.76 37 110 78.78 119.74
Chile (1999) 9426 155.98 154.46 9151 113.65 147.60
Colombia
(1999)
13 343 103.72 116.20 13 588 89.41 130.13
Costa Rica 1662 123.81 109.22 1431 93.74 117.16
Cuba 9536 138.71 170.93 7270 102.86 160.58
Ecuador 3346 84.86 79.73 3584 82.62 118.51
Mexico 27 841 91.18 96.02 29 940 84.18 127.47
Puerto Rico 2766 115.95 141.47 2092 75.30 105.28
Venezuela 8217 116.53 124.82 7993 96.47 143.23
Canada 34 096 148.33 163.07 30 015 105.71 146.53
USA 292 641 146.41 172.04 273 996 105.38 146.26
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than 20/100 000), Argentina, Brazil, Colombia and Venezuela
(with rates between 10 and 20/100 000 in men). Only Cuba,
Mexico and Puerto Rico had male rates lower than
10/100 000, but still higher than those in Canada (5.2/100 000)
and the USA (3.7/100 000). Stomach cancer mortality in
women was lower than in men, but the geographical differ-
ences were similar to those in men. Thus, rates were higher in
Chile, Costa Rica and Ecuador (over 12/100 000), and lower
in Argentina, Cuba and Puerto Rico (below 4/100 000). Corre-
sponding figures in Canada and the USA were 2.6/100 000
and 1.8/100 000, respectively.
Mortality from stomach cancer continued to steadily
decrease in the last three decades in most countries of Latin
America, including Colombia and Ecuador, where rates
showed increasing trends up to the 1980s. The reasons for the
generalized favorable patterns in gastric cancer rates in these
countries, as well as in the USA [4], Europe [1] and elsewhere
in the world, are not completely understood, but almost cer-
tainly include better food conservation—including refriger-
ation—a more varied and affluent diet [23, 29, 30], reduced
prevalence of Helicobacter pylori infection [31–33], and a
possible reduction in tobacco smoking, at least in men [34].
However, mortality from stomach cancer is still extremely
high in several Latin American countries, underlining the
importance of continuous monitoring and effort in the preven-
tion of this malignancy.
Intestines, chiefly colon and rectum
Mortality rates from cancer of the intestines in 2000 were
below 10/100 000 in most countries of Latin America, the only
exceptions being Argentina and Puerto Rico, where men had
rates of 14.9 and 11.9/100 000, respectively, and Cuba where
men had rates of 10.5/1000 and women of 12.8/100 000.
Corresponding values in Canada and the USA were around
14–15/100 000 in men and around 10/100 000 in women.
While in Canada and the USA mortality from colorectal cancer
showed continuous downward trends in the last three decades
[35], the pattern of colorectal cancer mortality in other
countries of the Americas was less favorable. In Argentina,
after a decline between the 1970s and the 1980s [36], rates
were stable, or even slightly increasing, in the two last dec-
ades. Increasing colorectal cancer mortality has also been
observed in several other countries of Latin America.
The low rates for colorectal cancer in countries like Brazil,
Colombia and Mexico, if not due to substantial underreport-
ing, likely reflect long-term favorable dietary habits in these
countries. However, patterns of colorectal cancer mortality are
unfavorable in these, as in other countries of Latin America,
probably as a consequence of modifications in dietary and life-
style habits, including an increase in the prevalence of over-
weight and obesity [37–39]. The relatively high colorectal
cancer mortality in Argentina is consistent with a role of red
meat (frequently consumed in this country) on colorectal car-
cinogenesis [23]. In Cuba, as in Costa Rica and Ecuador, col-
orectal cancer mortality rates (both all ages and truncated)
were higher in women than in men, but there is no satisfactory
explanation for the peculiar sex ratio in these countries [40,
41]. It appears that Cuban women not only have higher rates
of tobacco- (and alcohol-) related neoplasms, but also of col-
orectal cancer, which is moderately associated with alcohol
and tobacco consumption, but is probably related to nutrition
and diet [42].
Larynx
In 2000, male mortality from laryngeal cancer was high
in Argentina, Brazil and Cuba, with rates between 4 and
7/100 000 men, whereas countries with lower mortality were
Chile, Costa Rica and Ecuador, with rates between 0.9 and
1.7/100 000, i.e. similar to those reported in Canada and the
USA. Declines in mortality rates were observed in Argentina,
Chile, particularly in middle-aged men, Ecuador, and Puerto
Rico. A similar decrease in rates was observed in the USA
since the early 1970s, and in Canada since the late 1980s. A
steady upward trend since the late 1980s was observed in men
from Cuba and Venezuela, particularly in middle-aged ones.
The pattern in laryngeal cancer mortality was less clear in
other countries. Female rates were extremely low (between
0.1 and 0.7/100 000) in most American countries (except
Cuba, with a value of 1.2/100 000), and their trends were
unremarkable.
This is another neoplasm strongly related to tobacco smok-
ing and alcohol consumption [19], and its trends are consist-
ent, although somewhat less favorable, with those for oral,
pharyngeal and esophageal cancer, probably reflecting the pre-
dominant role of tobacco on laryngeal carcinogenesis [21].
Rates in Canada, and particularly in the USA, were lower than
in Latin American countries, as a consequence of a decrease
in tobacco consumption in men in the last decades [22]. Mod-
ern low tar yield cigarettes, which are deeply inhaled, are also
associated with lower laryngeal cancer risk, compared to older
ones [43]. Rates in Cuba, which are among the highest on a
worldwide scale [2] can also be related to cigar [44], and con-
sequently to black tobacco smoking [43, 45, 46].
Trachea, bronchus and lung
In 2000, lung cancer mortality rates in men were much lower
in most Latin American countries (rates between 13 and
21/100 000) than in North America (rates over 40/100 000).
The highest rates for men were registered in Argentina and
Cuba (35.0 and 38.3/100 000, respectively), whereas the low-
est rate was observed in Ecuador (7.7/100 000). In Argentina,
rates have steadily, though moderately, decreased in the last
three decades and are now lower than in the 1970s [36].
Conversely, in Cuba trends were stable overall, and slightly
increasing in middle-aged men. In other Latin American
countries, mortality from lung cancer, after a steady increase
up to the 1980s [47], showed a tendency to level off in the
last two decades, and even to decrease in middle-aged adults.
Only in Ecuador and Venezuela, are rates in lung cancer mor-
tality are still increasing. In the USA and Canada, substantial
declines were observed in overall lung cancer rates over
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the last two decades, and even greater declines in middle-aged
adults since the early 1990s [48, 49]. Female lung cancer
rates, in most Latin American countries, were still below
10/100 000, i.e. substantially lower than in North American
women (rates over 20/100 000), with the only exception of
Cuba (16.7/100 000). In several countries of Latin America,
as in the USA [50], lung cancer mortality in women has,
however, been increasing over the last decades [51].
Since the lung is the most important tobacco-related cancer
site, these trends essentially reflect smoking habits of sub-
sequent generations of men and women in various American
countries [22]. Thus, while in men they probably reflect a
decline in tobacco smoking in several countries, the persistent
comparatively low rates in women from most Latin American
countries indicate the scope of the intervention in tobacco con-
trol, to avoid a major lung cancer epidemic in Latin American
women in the near future. Occupational, mainly asbestos con-
trol, environmental and perhaps dietary factors of lung cancer
may also have exerted some influences on these favorable
trends in men [52].
Bone
Mortality rates from bone cancer were higher in most
countries in Latin America than they were in Canada and the
USA, with rates around 1/100 000 in men and slightly lower
in women. Since bone is one of the commonest sites of
metastasis [15], this may reflect less accurate death certifica-
tion in several Latin American countries compared with
North America. Mortality trends for bone neoplasms are
therefore difficult to interpret, but a general tendency to
decline can be observed in various Latin American countries,
as in Canada and the USA, probably reflecting improvements
in accuracy and validity of death certification over recent
calendar periods.
Breast
Female breast cancer mortality in 2000 was highest in Argen-
tina (20.7/100 000), with rates higher than those reported in
North America (i.e. around 18/100 000). In all other Latin
American countries, rates were around 12–15/100 000, with
the exception of Colombia, Ecuador and Mexico, where rates
were below 10/100 000. Trends in mortality rates over the last
decades were stable in Argentina, Chile and Cuba, while they
were increasing in other Latin American countries, particu-
larly those characterized by originally lower mortality. Con-
versely, in North America, breast cancer mortality has been
steadily declining, particularly in middle-aged women, in the
last two decades [53, 54].
The increase in female breast cancer trends is likely to be
related to changes in reproductive habits of subsequent cohorts
of American women, and in particular to a decreased fertility
[55]. Changes in dietary habits and other lifestyle factors [56],
and increased overweight [37] may also have played some role
in the recent upward trends in breast cancer. The declines in
breast cancer mortality in North America, together with the
stable rates in high and intermediate mortality areas from Latin
America, and the systematic upwards trends in the low mor-
tality ones indicate that rates tend to level off across the Amer-
icas, probably as a consequence of a general tendency towards
more uniform reproductive and lifestyle habits. The falls in
breast cancer mortality observed in Canada and the USA, as
well as in European countries [1], are probably attributable to
advancements in therapy, including the widespread use of
tamoxifen and adjuvant chemotherapy [57–59], although some
role of (mammographic) screening is also possible [60].
Uterus (cervix and corpus)
On the basis of death certification, it is not possible to dis-
tinguish cancers arising from cervix and from the corpus uteri
Figure 1. Age-standardized (world population) death rates per 100 000 from 14 cancer sites plus total cancer mortality in selected countries of the Ameri-
cas in 2000 (unless mentioned in parentheses).
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Figure 2. Trends in age-standardized (world population) death rates per 100 000 from 14 cancer sites plus total cancer mortality in selected countries of
the Americas, between 1970 and 2000; solid line and crosses, men, all ages; dotted line and crosses, men, truncated 35–64 years; solid line and open
squares, women, all ages; dotted line and open squares, women, truncated 35–64 years.
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(endometrium), and in several countries a substantial, though
variable, proportion of deaths from uterine cancers are attribu-
ted to ‘uterus unspecified’. However, since endometrial cancer
mortality is rare at younger ages, truncated trends at age
35–64 years are probably due mainly to cervical cancer.
Uterine cancer rates were exceedingly high in Latin Amer-
ica, essentially due to high rates of cervical cancer, as also
indicated by the high mortality in middle-aged women. Rates
were more than 15/100 000 overall and more than 30/100 000
at age 35–64 in Ecuador, Mexico and Venezuela, and more
than 10/100 000 in all women and more than 20/100 000 at
age 35–64 in most other countries. Only in Puerto Rico
were mortality rates lower (4.9/100 000 in all women, and
9.1/100 000 in middle-aged ones). Rates in North America
were around 4/100 000 overall and 7/100 000 truncated. A sys-
tematic and steady fall in uterine cancer mortality was
observed since the 1970s in most Latin American countries—
particularly in middle-aged women—with the exception of
Argentina and Cuba, where rates remained stable [61]. These
downward trends are probably due to a decline in cervical
cancer mortality, following some adoption, though still largely
inadequate, of cervical screening in these countries [62, 63].
However, the excess mortality in most Latin America (still
two- to four-fold higher than in North America) indicates the
need of more adequate screening programs to limit the conse-
quences of this avoidable cause of death [64, 65].
Ovary
Mortality data for ovarian cancer mortality were available
only for a few countries from Latin America, and for a limited
number of years. Ovarian cancer mortality rates in most Latin
American countries were comparatively low (between 2 and
5/100 000 women) on an international scale (rates around
5–6/100 000 in North America). However, upward trends
were observed in Argentina, Chile and Mexico in the last
decades.
This pattern probably reflects a number of factors, includ-
ing—as for breast cancer—the declined parity of subsequent
generations of Latin American women, although modifications
of dietary and other lifestyle factors may also have played
some role on ovarian cancer rates [66]. Conversely, in Canada
and the USA, ovarian cancer rates are now declining mainly
in middle-aged women, probably as a consequence of a more
widespread utilization of oral contraceptive in subsequent gen-
erations of women [67].
Prostate
In 2000, Cuba and Venezuela had the highest prostate cancer
mortality (rates over 20/100 000 overall), followed by Chile
and Costa Rica, with overall rates around 20/100 000. Rates at
age 35–64 years were exceedingly high in Cuba
(10.5/100 000) and Venezuela (8.6/100 000) [68]. The lowest
mortality was observed in Brazil and Mexico, with rates com-
parable to those of North America, i.e. around 12–13/100 000
overall and 5–6/100 000 truncated. In the last decades, overall
prostate cancer mortality showed a moderate upward trend in
all countries from Latin America. Since, however, no appreci-
able trends have been observed below age 65, it is likely that
the overall trends are influenced by recent changes in diagno-
sis and certification of prostate cancer in the elderly [69]. This
is particularly true for Chile, Costa Rica, Ecuador and Vene-
zuela, showing substantial diverging trends over the last dec-
ade for all age and truncated rates. In Canada and the USA,
mortality from prostate cancer has long been stable, but has
been declining in the last decade below age 65 years. In the
elderly, after a rise up to the 1990s, a subsequent fall in rates
has been observed [70].
Prostate cancer incidence essentially reflects the variable
adoption of prostate specific antigen (PSA) testing in various
populations. The favorable mortality trends observed in North
America, however, likely reflect an increase in survival rates,
due to improvements in treatment, including an earlier adop-
tion of trans-urethral resection of the prostate, as well as the
use of hormonal and radio-therapy for patients with locally
advanced prostate cancer [5, 71–73]. An earlier diagnosis of
the disease, following the introduction of PSA since the late
1980s or early 1990s, may also have played a role over the
last few years considered [74, 75]. In order to reduce prostate
cancer mortality in Latin American countries, it is therefore
important that diagnostic advancements and modern thera-
peutic approaches for prostate cancer are urgently adopted.
Testis
As for ovarian cancer, testicular cancer mortality data were
only available for a few countries and calendar years. In 2000,
rates in Latin America ranged between 0.3/100 000 in Cuba
and 1.3/100 000 in Chile. In North America, as in Europe [1],
mortality rates have been steadily declining since the 1970 s,
and in 2000 were about 0.2/100 000. Testicular cancer mor-
tality is thus now appreciably higher in Latin America than in
North America, reflecting an inadequate adoption of modern
platinum-based chemotherapy regimens, which have substan-
tially reduced mortality from testicular cancer in developed
areas of the world since the early 1970s [76, 77]. Again, this
calls for urgent adoption of modern treatment for a largely
avoidable cause of death in young men.
Bladder
In 2000, bladder cancer mortality rates in Argentina and Cuba
for men were at values comparable to those of North Ameri-
can men (i.e. about 4/100 000). Male rates were lower in other
countries of Latin America. In the last decades, rates showed
a downward trend in Argentina and Venezuela, as in Canada
and the USA, whereas trends were less clear in other
countries. Since bladder cancer is another neoplasm strongly
related to tobacco smoking [21], its mortality rates, with
recent declines for males in various countries of Latin
America, may reflect the patterns of tobacco smoking for sub-
sequent generations of American men. Moreover, a variable
role in the fall in bladder cancer mortality has probably been
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played by reduced occupational exposure to carcinogens, too
[78]. Higher bladder cancer mortality rates in Argentina and
Cuba may also be related to black tobacco smoking [79, 80].
Bladder cancer in women is rarer, and its rates show no clear
pattern of trends over time. As for lung cancer, the highest
rates (around 1/100 000) were observed in Cuba, where
tobacco smoking has long been common also in women.
Leukemias
In 2000, mortality from leukemias in men was between 3 and
5/100 000 in countries from Latin America, i.e. slightly lower
than that of Canada and the USA (rates around 5–6/100 000).
Values in women from Latin America were between 2 and
4/100 000, comparable with those of North America. In North
America, a steady decrease was observed since the early
1970s, following the adoption of integrated therapy regimens,
mainly in children and young adults [81–83]. Trends in
countries of Latin America were less consistent, with some
declines in Argentina, and even increases in Ecuador and
Mexico. As for testicular cancer, this would suggest some
delay in the adoption of modern effective therapy schemes,
although it is possible that these trends were also influenced
by improved accuracy of diagnosis and certification [84].
All neoplasms (benign and malignant)
Total cancer mortality in countries of Latin America showed
different patterns, which reflect the variable mortality rates
and trends for site-specific cancers. In 2000, the highest total
male cancer mortality was observed in Argentina and Chile,
with rates comparable with those of Canada and the USA, i.e.
about 150/100 000. For women, Chile and Cuba had the high-
est rates in Latin America (113.7 and 102.9/100 000, respect-
ively), again comparable with those of North America (around
105/100 000). These rates reflect the comparatively high mor-
tality from cancer of the stomach (for Chile), lung and intes-
tine (for Argentina) in men, and of stomach and uterus (for
Chile), intestines and lung (for Cuba) in women. Colombia,
Ecuador and Mexico [85] had the lowest male cancer mor-
tality, due to low mortality from stomach, colorectal and lung
cancer in those countries. For women, the lowest rates were in
Brazil and Puerto Rico, reflecting their low stomach and cervi-
cal cancer rates. In Argentina, Chile, Colombia, Costa Rica
and Venezuela cancer mortality rates tended to decline, par-
ticularly in men. Rates were stable in Ecuador and Puerto
Rico, and increasing in Mexico and Cuba.
Thus, mortality from some common cancers (including col-
orectal and lung) is still low in Latin America compared with
Canada and the USA, and decreasing trends have been
observed in the last decades for some cancer sites (including
stomach, uterus, lung and other tobacco-related cancers) in
several countries. However, mortality from female lung and
breast cancers has been increasing in most countries of Latin
America, and several countries still showed an extremely elev-
ated mortality from cancer of the cervix.
Favorable trends in cancer mortality in Latin America in
the near future would therefore require an integrated strategy
of prevention focused on the control of tobacco and alcohol,
particularly for countries like Cuba and Brazil, adoption of a
richer and more favorable diet for stomach cancer particularly
in Chile, Costa Rica and Colombia, as well as screening and
early diagnosis for cervical cancer. Adoption of therapeutic
advancements for selected neoplasms amenable to treatment,
including testicular cancer and leukemias, is also a priority for
most countries of Latin America [86].
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